Neurofibromatosis is a group of rare genetic disorders that cause benign tumors to form on nerve tissue. Tumors in this disorder are usually noncancerous (benign), but can sometimes become cancerous ...

McKinnon Galloway was diagnosed with neurofibromatosis type 2, a rare disorder that makes tumors grow around her nerves ...

Neurofibromatosis type 2 is most often diagnosed based on the presence of physical symptoms that are part of the specific diagnostic criteria for the disorder. Genetic testing for the NF2 mutation is ...

Neurofibromatosis type 2 (NF2) is an autosomal‐dominant disorder characterised by the development of multiple tumours, most notably bilateral vestibular schwannomas. These benign tumours originate ...

Vestibular schwannomas related to neurofibromatosis type 2 (NF2) are difficult to manage and are sometimes treated with a noninvasive option, stereotactic radiosurgery. A retrospective study conducted ...

It is suggested to submit at least 2 anatomically distinct tumors, however a single tumor can be provided. If a blood specimen is provided with the submitted tumor, confirmatory testing in the ...

Bevacizumab treatment at 7.5 mg/kg every 3 weeks results in improved hearing in approximately 35%-40% of patients with neurofibromatosis type 2 (NF2) and progressive vestibular schwannomas (VSs).

STAMFORD, Conn., Nov. 16, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients ...

SpringWorks Therapeutics, a Merck company, announced that the European Commission has granted conditional marketing authorization for EZMEKLY® (mirdametinib) for the treatment of symptomatic, ...

Radiochemotherapy with daily concomitant and adjuvant one week on/one week off temozolomide plus indomethacin in newly diagnosed glioblastoma: A phase II trial No significant financial relationships ...